Spectral to complete development of melanoma detection product this month
Spectral Molecular Imaging, a subsidiary of Cascade Technologies, will complete development of its new product SkinSpect, aimed at early detection of melanoma by hyperspectral imaging, in mid-September, ahead of schedule.
According to Cascade, the device incorporates new advances in component technologies (optics, cameras, displays, embedded computers and software), as well as experience derived from previous prototypes developed under federal funding and tested in the clinic. The spectral range covered is also extended, now ranging from 385 nm to 920 nm.
SkinSpect will be clinically tested on patients in early October at the University of Pittsburgh Medical Center Melanoma Center, said the Beverly Hills, Calif.-based Spectral.
According to Cascade, the device incorporates new advances in component technologies (optics, cameras, displays, embedded computers and software), as well as experience derived from previous prototypes developed under federal funding and tested in the clinic. The spectral range covered is also extended, now ranging from 385 nm to 920 nm.
SkinSpect will be clinically tested on patients in early October at the University of Pittsburgh Medical Center Melanoma Center, said the Beverly Hills, Calif.-based Spectral.